"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Astellas Pharma US Inc.","Astellas Pharma","$7,300,000","$0","$7,300,000","2014","20140416","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing",""
"OSI Pharmaceuticals LLC","Astellas Pharma","$67,000,000","$0","$67,000,000","2016","20160606","government-contracting-related offenses","False Claims Act and related","","Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to  pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer.  Genentech, located in South San Francisco, California, and OSI Pharmaceuticals, located in Farmingdale, New York, co-promote Tarceva, which is approved to treat certain patients with non-small cell lung cancer or pancreatic cancer.  OSI Pharmaceuticals LLC is the successor to OSI Pharmaceuticals Inc., which was acquired by Astellas Holding US Inc. in 2010 and converted to a limited liability company in 2011.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva",""
"Astellas Pharma US Inc.","Astellas Pharma","$100,000,000","$0","$100,000,000","2019","20190425","government-contracting-related offenses","False Claims Act and related","","Astellas Pharma US Inc. agreed to pay $100 million and Amgen Inc. agreed to pay $24.75 million to resolve allegations that they each violated the False Claims Act by illegally paying the Medicare copays for their own products, through purportedly independent foundations that the companies used as mere conduits.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/two-pharmaceutical-companies-agree-pay-total-nearly-125-million-resolve-allegations-they-paid",""
"Astellas","Astellas Pharma","$1,130,000","$0","$1,130,000","2013","20131118","government-contracting-related offenses","False Claims Act and related","","The Louisiana Attorney General's Office announced that it had obtained a total of $88 million in settlements from 25 pharmaceutical companies to resolve allegations they overcharged the state's Medicaid program.","state","agency action","Louisiana Attorney General","civil","","","","","","Louisiana","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131206104321/http://www.ag.state.la.us/Article.aspx?articleID=788&catID=2",""
"Astellas Pharma US Inc.","Astellas Pharma","$3,100,000","$3,100,000","$0","2014","20140416","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","Astellas Pharma agreed to pay $3.1 million to resolve multistate litigation alleging that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval. This was part of a larger $7.3 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-astellas-pharma-us-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing",""
"OSI Pharmaceuticals LLC","Astellas Pharma","$33,500,000","$0","$33,500,000","2016","20160606","government-contracting-related offenses","False Claims Act and related","","Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva",""
"OSI Pharmaceuticals LLC","Astellas Pharma","$2,200,000","$2,200,000","$0","2016","20160606","government-contracting-related offenses","False Claims Act and related","","Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay a total of $4.4 million to resolve multistate litigation alleging they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer and thus caused false claims to be submitted to state Medicaid programs. The announcement did not specify how much each company would pay. Here we assume the amount was divided evenly between them. This was part of a larger $67 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-genentech-inc ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva",""
